Summary of the technology
Bariatric surgery has emerged as an effective treatment for obesity, but there is limited evidence regarding the optimal candidate for each surgical procedure and remission rates of type 2 diabetes observed across published series vary. New tools are needed to better predict diabetes remission according to the surgical procedures in order to avoid unnecessarily aggressive surgeries and improve health outcomes.
The technology DiaSuc provides a method for selecting a bariatric surgical procedure for a patient, as well as an informative biomarker for predicting, before bariatric surgery, type 2 diabetes remission after bariatric surgery in a patient suffering from type 2 diabetes.
Description of the technology
The main innovate aspect of the method is that it is based on a single circulating metabolite that can be easily measured in blood. It is a single measurement that can be used independently of previously described pre-surgical factors and improves the current available scores to guide the decision on the type of bariatric surgery to achieve type 2 diabetes remission.
Current development status
DiaSuc provides a method for selecting a bariatric surgical procedure for a patient. The method has been described in a cohort of 45 subjects and confirmed in an independent validation cohort of 88 patients from a different centre.
Desired business relationship
Intellectual property status
Patent already applied for
Spanish Patent office
Technology Transfer Office